Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Year: 2024
Type: article
Study design: Clinical Trial
Source: Gynecologic Oncology
Authors: Lilian T. Gien, Danielle M. Enserro, Matthew S. Block, Steven Waggoner, Linda R. Duska, Andrea E. Wahner-Hendrickson, Premal H. Thaker, Floor Backes, Michael Kidd, Carolyn Y. Muller, Paul A. DiSilvestro, Allan Covens, David M. Gershenson, Kathleen N. Moore, Carol Aghajanian, Robert L. Coleman
Institutions: Sunnybrook Health Science Centre, Odette Cancer Centre, Roswell Park Comprehensive Cancer Center, Mayo Clinic, Case Western Reserve University, University of Virginia Medical Center, University of Virginia Cancer Center, University of Virginia, Washington University in St. Louis, The Ohio State University, Billings Clinic, University of New Mexico, UNM Comprehensive Cancer Center, Women & Infants Hospital of Rhode Island, The University of Texas MD Anderson Cancer Center, OU Health, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Memorial Sloan Kettering Cancer Center, The US Oncology Network
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, American Society of Clinical Oncology, Ohio State University, University of Washington, Case Western Reserve University, Case Comprehensive Cancer Center, Case Western Reserve University, Regeneron Pharmaceuticals, Novocure, PTC Therapeutics, Clovis Oncology, Alvin J. Siteman Cancer Center, Mersana Therapeutics, BeiGene, UVA Cancer Center, NRG Oncology, Syndax Pharmaceuticals, Verastem Oncology, Seagen, Natera, Eisai, National Institutes of Health, Genentech, Pharmacyclics, National Cancer Institute, Daiichi Sankyo Europe
OpenAlex ID: W4394680650